Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
822 10 |
Ultima descărcare din IBN: 2024-03-28 21:33 |
Căutarea după subiecte similare conform CZU |
616.233-007.272-036.12 (5) |
Pathology of the respiratory system. Complaints of the respiratory organs (777) |
SM ISO690:2012 POPA, Ana, MATCOVSCHI, Sergiu, CAPROŞ, Natalia, ŞVEŢ, Svetlana, LUPAN, Mihail. Evaluarea proteinei c reactive la pacienţii cu bronhopneumopatie obstructivă cronică în exacerbare. In: Arta Medica , 2018, nr. 2(67), pp. 60-62. ISSN 1810-1852. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Arta Medica | ||||||
Numărul 2(67) / 2018 / ISSN 1810-1852 /ISSNe 1810-1879 | ||||||
|
||||||
CZU: 616.233-007.272-036.12 | ||||||
Pag. 60-62 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Scopul studiului a fost de a evalua nivelul proteinei C reactive la pacienţii cu bronhopneumopatie obstructivă cronică in exacerbare. Studiul a fost efectuat pe un lot de 100 de pacienţi cu bronhopneumopatie obstructivă cronică GOLD II-IV in exacerbare, care au fost investigaţi clinic şi paraclinic conform ghidului GOLD 2017. Rezultatele investigației au arătat valori crescute ale CRP la toți pacienții cu bronhopneumopatie obstructivă cronică, predominant la cei cu tipul D și B cu grad sever de boală comparativ cu tipul C. Valoarea crescută a proteinei C reactive la pacienții cu bronhopneumopatie obstructivă cronică poate constitui un factor predictiv pentru o exacerbare severă actuală și fundamenta tratamentul oportun |
||||||
Cuvinte-cheie bronhopneumopatie cronică obstructivă în exacerbare, marker inflamator., proteina C reactivă |
||||||
|
Cerif XML Export
<?xml version='1.0' encoding='utf-8'?> <CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'> <cfResPubl> <cfResPublId>ibn-ResPubl-62299</cfResPublId> <cfResPublDate>2018-04-30</cfResPublDate> <cfVol>67</cfVol> <cfIssue>2</cfIssue> <cfStartPage>60</cfStartPage> <cfISSN>1810-1852</cfISSN> <cfURI>https://ibn.idsi.md/ro/vizualizare_articol/62299</cfURI> <cfTitle cfLangCode='RO' cfTrans='o'>Evaluarea proteinei c reactive la pacienţii cu bronhopneumopatie obstructivă cronică în exacerbare</cfTitle> <cfKeyw cfLangCode='RO' cfTrans='o'>bronhopneumopatie cronică obstructivă în exacerbare; proteina C reactivă; marker inflamator.</cfKeyw> <cfAbstr cfLangCode='RO' cfTrans='o'><p>Scopul studiului a fost de a evalua nivelul proteinei C reactive la pacienţii cu bronhopneumopatie obstructivă cronică in exacerbare. Studiul a fost efectuat pe un lot de 100 de pacienţi cu bronhopneumopatie obstructivă cronică GOLD II-IV in exacerbare, care au fost investigaţi clinic şi paraclinic conform ghidului GOLD 2017. Rezultatele investigației au arătat valori crescute ale CRP la toți pacienții cu bronhopneumopatie obstructivă cronică, predominant la cei cu tipul D și B cu grad sever de boală comparativ cu tipul C. Valoarea crescută a proteinei C reactive la pacienții cu bronhopneumopatie obstructivă cronică poate constitui un factor predictiv pentru o exacerbare severă actuală și fundamenta tratamentul oportun</p></cfAbstr> <cfAbstr cfLangCode='EN' cfTrans='o'><p>The aim of the study was to evaluate the level of C reactive protein in patients with chronic obstructive pulmonary disease in exacerbation. The study was performed on a group of 100 patients with chronic obstructive pulmonary disease GOLD II-IV in exacerbation, that were clinically and paraclinically investigated according to the GOLD 2017 guideline. The results of the study showed elevated C reactive protein values in all patients with chronic obstructive pulmonary disease, predominantly in those with D and B types compared to type C. Increased C reactive protein value in patients with chronic obstructive pulmonary disease may be a predictive factor for a current severe exacerbation and argue the oportun treatment. </p></cfAbstr> <cfResPubl_Class> <cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId> <cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId> <cfStartDate>2018-04-30T24:00:00</cfStartDate> </cfResPubl_Class> <cfResPubl_Class> <cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId> <cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId> <cfStartDate>2018-04-30T24:00:00</cfStartDate> </cfResPubl_Class> <cfPers_ResPubl> <cfPersId>ibn-person-45682</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2018-04-30T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-11372</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2018-04-30T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-10755</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2018-04-30T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-12677</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2018-04-30T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-18900</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2018-04-30T24:00:00</cfStartDate> </cfPers_ResPubl> </cfResPubl> <cfPers> <cfPersId>ibn-Pers-45682</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-45682-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2018-04-30T24:00:00</cfStartDate> <cfFamilyNames>Попа</cfFamilyNames> <cfFirstNames>А.</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-11372</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-11372-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2018-04-30T24:00:00</cfStartDate> <cfFamilyNames>Matcovschi</cfFamilyNames> <cfFirstNames>Sergiu</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-10755</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-10755-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2018-04-30T24:00:00</cfStartDate> <cfFamilyNames>Капрош</cfFamilyNames> <cfFirstNames>Н.</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-12677</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-12677-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2018-04-30T24:00:00</cfStartDate> <cfFamilyNames>Şveţ</cfFamilyNames> <cfFirstNames>Svetlana</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-18900</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-18900-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2018-04-30T24:00:00</cfStartDate> <cfFamilyNames>Lupan</cfFamilyNames> <cfFirstNames>Mihail</cfFirstNames> </cfPersName_Pers> </cfPers> </CERIF>